EUVIMEDEUVIMED entdecken
Validierungsstudie

External validation of bleeding and recurrence risk scores in patients with cancer-associated thrombosis on anticoagulant therapy

Maria Barca-Hernando, Carmen Rosa-Linares, Victor Garcia-Garcia, Sergio Lopez-Ruz, Teresa Elias-Hernandez, Remedios Otero-Candelera, Henry Andrade-Ruiz, Melisa González-Acosta, Luis Jara-Palomares

Thrombosis Research · 2026-07 · 263 · 109751

DOI: 10.1016/j.thromres.2026.109751 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Thrombosis Research, 2026-07. Verfasst von Maria Barca-Hernando und 8 weiteren Autor:innen. Beteiligte Einrichtung: Respiratory Unit, Virgen del Rocio University Hospital, Seville, Spain. Electronic address: maria.barca.sspa@juntadeandalucia.es. Hauptthemen laut MEDLINE: Anticoagulants, Hemorrhage, Neoplasms, Thrombosis. Die Arbeit nennt 39 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND Cancer-associated thrombosis (CAT) requires balancing recurrent venous thromboembolism (VTE) risk against bleeding from anticoagulation. Most risk scores are not specific for CAT, limiting their accuracy, while cancer-specific tools lack robust external validation. OBJECTIVES This study aimed to externally validate risk scores for predicting bleeding and recurrent VTE within 6 months in patients with CAT receiving anticoagulants. PATIENTS/METHODS We conducted a retrospective cohort study of 1203 patients with CAT from a hospital registry between 2007 and 2022. Primary outcomes were clinically relevant bleeding (CRB) and recurrent VTE within 6 months. Ten bleeding (B-CAT, CAT-BLEED, ACCP-VTE, HAS-BLED, HEMORR2HAGES, VTE-BLEED, Kuijer, Martinez, Nieto and RIETE) and four recurrence scores (Ottawa, RIETE, HERDOO2, DASH) were assessed. Predictive performance was evaluated using the area under the receiver operating characteristic curve (AUC) for discrimination. For risk stratification analyses, odds ratios (OR) were calculated to assess the association between risk categories and primary outcomes. RESULTS Among 1203 patients (mean age 63.9 ± 12.7 years; 52.6% male), 65 experienced CRB (5.4%) and 60 developed recurrent VTE (5.0%) within 6 months. Of the bleeding models, only the original three-category B-CAT score showed acceptable discriminative performance (c-statistic 0.70; 95% CI: 0.64-0.75), stratifying patients into low-, intermediate-, and high-risk groups with CRB incidences of 1.6%, 5.8%, and 20.4% (p < 0.001). For recurrent VTE, only the modified DASH score showed modest predictive ability (c-statistic 0.58; 95% CI: 0.52-0.64; p = 0.01), with recurrent VTE rates of 3.3% in the low-risk group and 6.3% in the high-risk group. CONCLUSIONS In this real-world CAT cohort, the B-CAT score was externally validated as the best predictor of 6-month bleeding risk, while the modified DASH score showed only modest predictive ability for VTE recurrence.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticoagulantsHemorrhageNeoplasmsThrombosisHumansMaleFemaleMiddle AgedRecurrenceRetrospective StudiesAgedRisk FactorsRisk AssessmentVenous Thromboembolism

Stichwörter der Autor:innen

AnticoagulantsBleedingCancerRecurrenceVenous thromboembolism

Substanzen

Anticoagulants

Autor:innen und Institutionen

  • Respiratory Unit, Virgen del Rocio University Hospital, Seville, Spain. Electronic address: maria.barca.sspa@juntadeandalucia.es.
  • Respiratory Unit, Virgen del Rocio University Hospital, Seville, Spain.
  • Respiratory Unit, Virgen del Rocio University Hospital, Seville, Spain; CIBERES, Carlos III Health Institute, Madrid, Spain.
  • Foundation for Health Research Management, FISEVI, Seville, Spain.
  • Respiratory Unit, Virgen del Rocio University Hospital, Seville, Spain; CIBERES, Carlos III Health Institute, Madrid, Spain. Electronic address: luisj.jara.sspa@juntadeandalucia.es.

Zitieren

APA

Barca-Hernando, M., Rosa-Linares, C., Garcia-Garcia, V., Lopez-Ruz, S., Elias-Hernandez, T., Otero-Candelera, R., Andrade-Ruiz, H., González-Acosta, M., & Jara-Palomares, L. (2026). External validation of bleeding and recurrence risk scores in patients with cancer-associated thrombosis on anticoagulant therapy. Thrombosis Research, 263, 109751. https://doi.org/10.1016/j.thromres.2026.109751

Vancouver

Barca-Hernando M, Rosa-Linares C, Garcia-Garcia V, Lopez-Ruz S, Elias-Hernandez T, Otero-Candelera R, et al. External validation of bleeding and recurrence risk scores in patients with cancer-associated thrombosis on anticoagulant therapy. Thrombosis Research. 2026;263:109751. doi:10.1016/j.thromres.2026.109751

BibTeX
@article{BarcaHernando2026,
  author = {Barca-Hernando, Maria and Rosa-Linares, Carmen and Garcia-Garcia, Victor and Lopez-Ruz, Sergio and Elias-Hernandez, Teresa and Otero-Candelera, Remedios and Andrade-Ruiz, Henry and González-Acosta, Melisa and Jara-Palomares, Luis},
  title = {External validation of bleeding and recurrence risk scores in patients with cancer-associated thrombosis on anticoagulant therapy},
  journal = {Thrombosis Research},
  year = {2026},
  volume = {263},
  pages = {109751},
  doi = {10.1016/j.thromres.2026.109751}
}
Kostenlos starten →